Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Ayala Asset Purchase Agreement Common Stock	Ayala Asset Purchase Agreement Additional Paid-in Capital	Ayala Asset Purchase Agreement	License agreement with Zentalis Pharmaceuticals, Inc Common Stock	License agreement with Zentalis Pharmaceuticals, Inc Additional Paid-in Capital	License agreement with Zentalis Pharmaceuticals, Inc	BMS License Agreement Common Stock	BMS License Agreement Additional Paid-in Capital	BMS License Agreement	ATM Common Stock	ATM Additional Paid-in Capital	ATM	Public offering Common Stock	Public offering Additional Paid-in Capital	Public offering	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at Dec. 31, 2022																$ 1	$ 132,653		$ (116,001)	$ 16,653
Balance (in shares) at Dec. 31, 2022																12,128,843
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																	1,200			1,200
Issuance of common stock											$ 34	$ 34					221			221
Issuance of common stock (in shares)										5,925						55,250
Vesting of restricted stock awards																	24			24
Vesting of restricted stock awards (in shares)																4,166
Net loss																			(4,270)	(4,270)
Balance at Mar. 31, 2023																$ 1	134,132		(120,271)	13,862
Balance (in shares) at Mar. 31, 2023																12,194,184
Balance at Dec. 31, 2022																$ 1	132,653		(116,001)	$ 16,653
Balance (in shares) at Dec. 31, 2022																12,128,843
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock warrants (in shares)																				0
Net loss																				$ (14,172)
Balance at Sep. 30, 2023																$ 1	136,248		(130,173)	6,076
Balance (in shares) at Sep. 30, 2023																12,202,516
Balance at Mar. 31, 2023																$ 1	134,132		(120,271)	13,862
Balance (in shares) at Mar. 31, 2023																12,194,184
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																	998			998
Vesting of restricted stock awards																	35			35
Vesting of restricted stock awards (in shares)																6,249
Net loss																			(5,557)	(5,557)
Balance at Jun. 30, 2023																$ 1	135,165		(125,828)	9,338
Balance (in shares) at Jun. 30, 2023																12,200,433
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																	1,072			1,072
Vesting of restricted stock awards																	11			$ 11
Vesting of restricted stock awards (in shares)																2,083
Exercise of common stock warrants (in shares)																				0
Net loss																			(4,345)	$ (4,345)
Balance at Sep. 30, 2023																$ 1	136,248		(130,173)	6,076
Balance (in shares) at Sep. 30, 2023																12,202,516
Balance at Dec. 31, 2023																$ 4	342,663	$ 22	(222,807)	119,882
Balance (in shares) at Dec. 31, 2023																43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																	2,159			2,159
Issuance of common stock		$ 50,645	$ 50,645		$ 23,388	$ 23,388							$ 2	$ 215,408	$ 215,410
Issuance of common stock (in shares)	2,175,489			2,298,586									11,500,000
Exercise of stock options																	171			171
Exercise of stock options (in shares)																125,704
Exercise of common stock warrants																	3,427			3,427
Exercise of common stock warrants (in shares)																342,686
Unrealized gain (loss) on marketable securities																		(18)		(18)
Net loss																			(129,492)	(129,492)
Balance at Mar. 31, 2024																$ 6	637,861	4	(352,299)	285,572
Balance (in shares) at Mar. 31, 2024																59,694,243
Balance at Dec. 31, 2023																$ 4	342,663	22	(222,807)	$ 119,882
Balance (in shares) at Dec. 31, 2023																43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)												0
Exercise of stock options (in shares)																				566,548
Exercise of common stock warrants (in shares)																				373,057
Net loss																				$ (212,714)
Balance at Sep. 30, 2024																$ 6	650,351	70	(435,521)	214,906
Balance (in shares) at Sep. 30, 2024																60,422,062
Balance at Mar. 31, 2024																$ 6	637,861	4	(352,299)	285,572
Balance (in shares) at Mar. 31, 2024																59,694,243
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																	3,227			3,227
Exercise of stock options																	859			859
Exercise of stock options (in shares)																289,041
Exercise of common stock warrants																	304			304
Exercise of common stock warrants (in shares)																30,371
Unrealized gain (loss) on marketable securities																		(2)		(2)
Net loss																			(36,122)	(36,122)
Balance at Jun. 30, 2024																$ 6	642,251	2	(388,421)	253,838
Balance (in shares) at Jun. 30, 2024																60,013,655
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																	4,892			4,892
Issuance of common stock								$ 2,699	$ 2,699
Issuance of common stock (in shares)							230,415
Exercise of stock options																	509			$ 509
Exercise of stock options (in shares)																177,992
Exercise of common stock warrants (in shares)																				0
Unrealized gain (loss) on marketable securities																		68		$ 68
Net loss																			(47,100)	(47,100)
Balance at Sep. 30, 2024																$ 6	$ 650,351	$ 70	$ (435,521)	$ 214,906
Balance (in shares) at Sep. 30, 2024																60,422,062